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Abstract
Background: Burkholderia cenocepacia are opportunistic Gram-negative bacteria that can cause
chronic pulmonary infections in patients with cystic fibrosis. These bacteria demonstrate a high-
level of intrinsic antibiotic resistance to most clinically useful antibiotics complicating treatment.
We previously identified 14 genes encoding putative Resistance-Nodulation-Cell Division (RND)
efflux pumps in the genome of B. cenocepacia J2315, but the contribution of these pumps to the
intrinsic drug resistance of this bacterium remains unclear.
Results: To investigate the contribution of efflux pumps to intrinsic drug resistance of B.
cenocepacia J2315, we deleted 3 operons encoding the putative RND transporters RND-1, RND-
3, and RND-4 containing the genes BCAS0591-BCAS0593, BCAL1674-BCAL1676, and BCAL2822-
BCAL2820. Each deletion included the genes encoding the RND transporter itself and those
encoding predicted periplasmic proteins and outer membrane pores. In addition, the deletion of
rnd-3 also included BCAL1672, encoding a putative TetR regulator. The B. cenocepacia rnd-3 and rnd-
4 mutants demonstrated increased sensitivity to inhibitory compounds, suggesting an involvement
of these proteins in drug resistance. Moreover, the rnd-3 and rnd-4 mutants demonstrated reduced
accumulation of N-acyl homoserine lactones in the growth medium. In contrast, deletion of the rnd-
1 operon had no detectable phenotypes under the conditions assayed.
Conclusion: Two of the three inactivated RND efflux pumps in B. cenocepacia J2315 contribute
to the high level of intrinsic resistance of this strain to some antibiotics and other inhibitory
compounds. Furthermore, these efflux systems also mediate accumulation in the growth medium
of quorum sensing molecules that have been shown to contribute to infection. A systematic study
of RND efflux systems in B. cenocepacia is required to provide a full picture of intrinsic antibiotic
resistance in this opportunistic bacterium.
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Burkholderia cenocepacia is a member of the Burkholderia
cepacia complex (Bcc), a group of phenotypically similar
Gram-negative bacteria [1] that are opportunistic patho-
gens and sometimes cause serious life-threatening infec-
tions in cystic fibrosis (CF) patients [2,3]. Infection in CF
patients may result in asymptomatic carriage, but often
leads to a rapid decline of the lung function and in some
cases to the "cepacia syndrome", characterized by necro-
tizing pneumonia and sepsis [4].
B. cenocepacia and other members of the Bcc demonstrate
high-levels of intrinsic resistance to most clinically rele-
vant antibiotics, complicating the treatment of the infec-
tion [5]. Multi-drug resistance in CF isolates is defined as
resistance to all of the agents in two of three classes of
antibiotics, such as quinolones, aminoglycosides, and -
lactam agents, including monobactams and carbapenems
[6]. Multiple antibiotic resistances in Bcc bacteria have
been attributed to reduced permeability of the bacterial
outer membrane [7-9], expression of antibiotic modifying
enzymes [10], and alteration of cellular targets [11]. Infor-
mation relating to the contribution that drug efflux sys-
tems play in the drug resistance of Bcc bacteria is limited,
as only a few multi-drug efflux pumps have been
described to date in some clinical isolates [12-14]. In con-
trast, the contribution of multidrug efflux systems to anti-
biotic resistance in clinical isolates of Pseudomonas
aeruginosa, another CF pathogen, is well documented.
Two P. aeruginosa efflux pumps, MexAB-OprM and
MexXY-OprM, contribute to intrinsic multidrug resist-
ance, while MexCD-OprJ and MexEF-OprN are responsi-
ble for the acquired antimicrobial resistance of different
mutant strains [15].
RND transporters are important mediators of multi-drug
resistance in Gram-negative bacteria [16]. RND transport-
ers form protein complexes that span both the cytoplas-
mic and outer membrane. The complex comprises a
cytoplasmic membrane transporter protein, a periplas-
mic-exposed membrane adaptor protein, and an outer-
membrane channel protein. The Escherichia coli AcrAB-
TolC and the P. aeruginosa MexAB-OprM complexes are
extremely well characterized and the three-dimensional
structures of various components have been resolved [17-
21].
Two RND type multi-drug efflux pumps, AmrAB-OprA
and BpeAB-OprB, have been described in Burkholderia
pseudomallei (the causative agent of melioidosis) and both
confer resistance to aminoglycosides and macrolides
[22,23]. The contribution of BpeAB-OprB and AmrAB-
OprA, to the intrinsic resistance of B. pseudomallei to gen-
tamicin, streptomycin and erythromycin explains why
aminoglycoside--lactam combinations, which are com-
monly used to treat suspected cases of community-
acquired sepsis in any part of the world, are ineffective for
the treatment of melioidosis [24]. Furthermore, the trans-
port of acyl homoserine lactones, involved in quorum-
sensing systems of B. pseudomallei, also requires the
BpeAB-OprB efflux pump [25]. Thus, targeted inhibition
of BpeAB-OprB could be therapeutically beneficial.
Several possible strategies can be considered to specifi-
cally block the activity of these drug efflux pumps, such as
jamming the outer membrane channel, generating com-
petition at the inner membrane pump, altering the pump
assembling or collapsing the energy component of the
mechanism [26]. The activity of efflux inhibitors, such as
diamine compounds, has been demonstrated in animal
models of P. aeruginosa infections and two of them are in
preclinical development [26].
In B. cenocepacia the significance of RND efflux systems
has not been determined. However, a salicylate-regulated
efflux pump that is conserved among members of the Bcc
has been identified [27,28]. We are focusing our research
in the B. cenocepacia J2315 strain. This strain is a proto-
typic isolate belonging to an epidemic clone that has
spread by cross infection to CF patients in Europe and
North America [29]. Previously, we identified 14 genes
encoding putative RND efflux pumps in the genome of B.
cenocepacia J2315 [30]. After the completion of the whole
genome sequence [31], two additional genes encoding
RND pumps were discovered. Reverse transcriptase analy-
ses showed that some of these genes are indeed tran-
scribed at detectable levels. As a first step towards
understanding the contribution of RND pumps to B. cen-
ocepacia antibiotic resistance we deleted genes encoding
putative efflux pumps, RND-1, RND-3, and RND-4, con-
taining the genes BCAS0591-BCAS0593 (located on chro-
mosome 3), BCAL1674-BCAL1676, and BCAL2822-
BCAL2820 (located on chromosome 1), respectively. In a
previous publication, the genes encoding the membrane
transporter component of the efflux pump, BCAS0592,
BCAL1675, and BCAL2821 were referred to as Orf1, Orf3,
and Orf4, respectively [30]. In this investigation we show
that deletion of rnd-3 and rnd-4 genes is associated with
increased sensitivity to certain antibiotics and reduced
secretion of quorum sensing molecules.
Results and Discussion
B. cenocepacia BCAS0592, BCAL1675, and BCAL2821 
encode RND-type transporters
We characterized 3 efflux systems of B. cenocepacia J2315
by deletion mutagenesis. These systems were selected
based on their high homology to the well-characterized
Mex efflux pumps in P. aeruginosa. One of the identified
operons, located on chromosome 3, encodes RND-1 and
comprises the genes BCAS0591-BCAS0592-BCAS0593Page 2 of 11
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BCAS0591 encodes a predicted 418-aa membrane fusion
protein, followed by the RND transporter gene predicted
to encode a 1065-aa protein, and BCAS0593 encoding a
475-aa outer membrane protein. Amino acid sequence
analysis of the BCAS0592 gene product revealed con-
served motifs and the characteristic predicted structure
common to the inner membrane proteins of the RND
efflux complex. Topologically BCAS0592 is a polypeptide
with 12 predicted transmembrane alpha helices and two
large periplasmic loops between transmembrane helices
1-2 and 7-8 [30]. A search using the National Center for
Biotechnology Information protein database with the
BLASTP program http://www.ncbi.nlm.nih.gov/ revealed
that the components of this efflux system shared amino
acid sequence identity with the well characterized AcrAB-
TolC, BpeAB-OprB, and MexAB-OprM RND efflux pumps
of E. coli, B. pseudomallei, and P. aeruginosa, respectively. In
particular, BCAS0592 shared 60, 59, 56% amino acid
identity with the RND transporters AcrB (E. coli), BpeB (B.
pseudomallei), and MexB (P. aeruginosa), respectively.
BCAS0591 shared 53, 50, and 50% amino acid identity
with the membrane fusion proteins AcrA (E. coli), MexA
(P. aeruginosa), and BpeA (B. pseudomallei). On the other
hand, BCAS0593 shared 52% amino acid identity with
OprM (P. aeruginosa) and 49% with OprB (B. pseudomal-
lei), both of which are outer membrane pore proteins.
The operon encoding RND-3 is located on chromosome 1
and spans nucleotides 1830038 to 1834638. The first
gene, BCAL1674, encodes the membrane fusion protein, a
predicted 406-aa protein. The product of the downstream
gene is a predicted 1046-aa protein that functions as an
RND transporter. The third gene, BCAL1676, encodes the
486-aa outer membrane pore protein [Fig. 1]. BLASTP
results revealed that BCAL1674 had 79 and 48% identity
with the membrane fusion proteins AmrA (B. pseudomal-
lei) and MexC (P. aeruginosa), while BCAL1675 was simi-
lar to AmrB (B. pseudomallei, 86%) and to MexD of P.
aeruginosa (52%), both encoding the RND transporter.
BCAL1676 was highly related to the outer membrane pro-
teins OprA of B. pseudomallei (78% of identity) and OprM
of P. aeruginosa (47%) and again possessed the predicted
conserved structural features of outer membrane proteins
that function in RND efflux systems. A gene encoding a
predicted TetR family regulator protein (BCAL1672) is
located upstream of BCAL1674 but is transcribed in the
opposite direction [Fig. 1].
Lastly, the predicted operon encoding RND-4, comprising
the genes BCAL2820, BCAL2821 and BCAL2822, is
located on chromosome 1 and spans nucleotides
3095788 to 3101801 [Fig. 1]. BCAL2821 encodes the
1066-aa RND transporter protein, which is highly related
to BpeB from B. pseudomallei (94% identity) and to MexB
(P. aeruginosa, 64% identity). BCAL2820 encodes the 507-
aa outer membrane protein related to OprB (B. pseudoma-
llei, 84% identity) and to OprM from P. aeruginosa (53%
identity). BCAL2822 encodes a predicted 424-aa mem-
brane fusion protein highly similar to BpeA from B. pseu-
domallei (89% identity) and to MexA from P. aeruginosa
(54% identity).
To demonstrate a role for these efflux pumps in the intrin-
sic antibiotic resistance of B. cenocepacia J2315, we
attempted the construction of single deletion mutants of
each rnd gene using the method described by Flannagan et
al. [32] (see Methods). The deletion mutagenesis strategy
requires expression of the endonuclease I-SceI and allows
for the creation of unmarked gene deletions. While
attempting to generate the deletion mutants we encoun-
tered difficulties selecting recombinant colonies at a high
concentration of antibiotics. Similarly we also failed to
identify positive colonies having targeted integration of
the deletion plasmid. The latter was particularly difficult
for our initial attempts to get single deletions of each of
the rnd genes. We reasoned that the flanking regions of the
rnd genes, which are cloned into the mutagenesis plasmid
pGPI-SceI to mediate targeted integration into the chro-
mosome, share significant sequence identity between dif-
ferent rnd genes throughout the B. cenocepacia genome.
Due to these difficulties we concluded that single gene
deletions could not be possible using the I-SceI mutagen-
esis strategy. To circumvent this problem we generated
plasmids designed to delete the entire operons encoding
the three different efflux systems, as the DNA flanking the
operons was not similar between different operons encod-
Genetic map of B. cenocepacia rnd operons containing the BCAS0592, BCAL1675, and BCAL2821 genesFigure 1
Genetic map of B. cenocepacia rnd operons contain-
ing the BCAS0592, BCAL1675, and BCAL2821 genes. 
Gene positions and orientations are shown. Membrane 
fusion protein encoding genes are depicted in green, the 
RND encoding ones in yellow (the previous name attributed 
to these genes in reported in parentheses), and the genes 
encoding outer membrane proteins are in white. The puta-
tive repressor gene BCAL1672 is depicted in pink.
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strains D1 (BCAS0591-BCAS0593), D3 (BCAL1672-
BCAL1676), and D4 (BCAL2820-BCAL2822). In the case
of strain D3, the deletion not only included the rnd
operon but also BCAL1672, encoding a putative TetR reg-
ulator. The presence of the correct deletion in each strain
was confirmed by PCR analysis and Southern blot hybrid-
ization (data not shown).
Effect of deletion of efflux pumps operons on B. 
cenocepacia J2315 drug resistance
To determine if the deletion of the targeted efflux pumps
altered susceptibility to antimicrobial agents we exposed
the parental strain J2315 and the mutants D1, D3, and D4
to a variety of antimicrobial compounds. Table 1 summa-
rizes the minimum inhibitory concentrations (MICs) of
the different compounds tested. The wild-type strain,
J2315, demonstrates a high intrinsic level of resistance to
a variety of drugs including -lactams, aminoglycosides,
fluoroquinolones, and ethidium bromide. Strain D1
(BCAS0591-BCAS0593) did not show any increased sus-
ceptibility as compared to the parental strain J2315. The
inability to demonstrate growth inhibition of B. cenocepa-
cia D1 is likely due to functional redundancy as this strain
carries genes encoding 15 other RND efflux pumps that
could compensate for deletion of the rnd-1 operon. On
the other hand, not all the RND efflux pumps seem to
share the same drug specificity, and the selected com-
pounds could be extruded from the cell by other trans-
porters of non-RND families. In contrast, the deletion of
the complete BCAL1674-BCAL1675-BCAL1676 operon
(encoding the RND-3 efflux pump) and the BCAL1672
gene, encoding a putative transcriptional regulator, led to
a 8-fold reduction in the MIC values for nalidixic acid as
compared to the control strain J2315 [Table 1]. This result
demonstrates that RND-3 is indeed required for antibiotic
resistance and that, at least for the compounds tested,
demonstrates nalidixic acid specificity as this was the only
MIC altered in the mutant strain.
As already mentioned, the proteins BCAL1674,
BCAL1675, and BCAL1676 that comprise the rnd-3
operon share strong sequence similarity to RND efflux
pump AmrAB-OprA from B. pseudomallei which is respon-
sible for the efflux of aminoglycosides and macrolides in
that Burkholderia species [33]. We previously showed that
the gene encoding the pump protein (orf3) was expressed
at detectable levels by RT-PCR. Assuming that RND-3 is
functionally similar to AmrAB-OprA, the lack of
aminoglycoside and macrolide resistance in the B. cenoce-
pacia D3 mutant may be due to an alternative efflux pump
or resistance mechanism against aminoglycosides and
macrolides. To address the notion of RND efflux pump
redundancy, we are in the process of generating a com-
plete library of RND deletion mutants that can be
screened for drug sensitivity. Furthermore the I-SceI dele-
tion strategy makes it possible the construction of strains
carrying multiple RND gene deletions, which we are also
pursuing.
The B. cenocepacia D4 deletion mutant demonstrated a 4
to 16-fold increase in drug susceptibility to several of the
antimicrobials tested, indicating that RND-4 plays an
important role in the intrinsic antibiotic resistance of B.
cenocepacia [Table 1]. In particular, strain D4 is more sus-
ceptible than the parental strain J2315 when exposed to
aztreonam, chloramphenicol, gentamicin, tobramicin,
and to different fluoroquinolones, such as nalidixic acid,
ciprofloxacin, levofloxacin, norfloxacin, and sparfloxacin.
Furthermore, the MIC of ethidium bromide was more
than 16-fold lower in D4 than in J2315 [Table 1]. The MIC
values for other drugs such as ampicillin, ceftazidime,
meropenem, piperacillin, erythromycin, and kanamycin
were not altered in D4 as compared to J2315 (data not
shown). Increased sensitivity to many antimicrobials of
therapeutic importance might suggest that inhibition of
RND-4 function could be of benefit to CF patients colo-
nized with B. cenocepacia.
Effect of broad-spectrum efflux pump inhibitor MC-
207,110 on B. cenocepacia J2315 and the RND deletion 
mutants D1, D3 and D4
It has been reported that MC-207,110 efflux inhibitor has
a potentiating effect in P. aeruginosa, where it lowers the
MIC of different fluoroquinolones [34,35]. We tested the
effect of this efflux inhibitor on B. cenocepacia J2315 and
the deletion mutants D1, D3, and D4. To initiate this
analysis we determined the MIC of MC-207,110 for our
bacterial strains to determine whether this compound was
itself bactericidal. Exposure of J2315, D1 and D3 to MC-
207,110 yielded an MIC value of 640 g/ml. In contrast,
strain D4 demonstrated a MIC to MC-207,110 of 320 g/
Table 1: Antimicrobial susceptibilities of B. cenocepacia J2315, 
D3, and D4 strains
Compound MIC (g/ml)
J2315 wt D3 D4
Aztreonam 2000 2000 250
Ethidium bromide >2000 >2000 125
Chloramphenicol 4 4 <1
Gentamicin >2000 >2000 1000
Tobramicin 1000 1000 250
Nalidixic acid 16 2 4
Ciprofloxacin 8 8 2
Levofloxacin 4 4 0.5
Norfloxacin 32 32 8
Sparfloxacin 8 8 1Page 4 of 11
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rial effects and that RND-4 is required at least in part for
resistance to this compound. Next, the MICs of the com-
pounds previously used to determine resistance profiles
described above were re-assessed in the presence of 40 g/
ml of MC-207,110 by the agar plate method. This concen-
tration was selected as it is well below the MIC value deter-
mined for each strain. Exposure of the parental strain
J2315 or the mutant strains generated in this study to MC-
207,100 did not alter the MIC profile for any of the strains
tested. This is consistent with previous observations in B.
pseudomallei where this compound did not increase drug
sensitivity [22].
Efflux of levofloxacin in B. cenocepacia J2315 and the D4 
mutant
Given that B. cenocepacia D4 demonstrated 8-fold reduc-
tion in its MIC for levofloxacin as compared to J2315, we
determined whether the levofloxacin resistance mecha-
nism was due to active drug efflux mediated by RND-4.
This was performed by a fluorometric levofloxacin uptake
assay (see Methods). Fig. 2 shows that D4 mutant bacteria
rapidly accumulate levofloxacin achieving a steady-state
level within 5 minutes of incubation in the presence of the
drug. Levofloxacin accumulation was greatly increased (~
80% higher) in D4 mutant bacteria as compared to the
parental strain J2315. These results strongly support the
notion that the RND-4 efflux pump comprised of
BCAL2820, BCAL2821 and BCAL2822 functions as a lev-
ofloxacin efflux system. As a control, the uptake assay was
also performed on mutant D1, which does not show any
phenotype regarding the resistance profile (see Table 1).
The D1 strain behaved like the wild-type strain J2315 [Fig.
2], suggesting that increased levofloxacin uptake in the
mutant strains is not due to a general defect in membrane
permeability.
Moreover, to determine whether the accumulation of lev-
ofloxacin was energy-dependent, reserpine was added to
cells 2.5 min after the addition of levofloxacin. As shown
in Fig. 2, in the presence of reserpine, in the wild-type
strain and D1 mutant, the accumulation of levofloxacin
increased to levels close to the values shown by D4
mutant. This demonstrates that the accumulated levels of
levofloxacin were the same under de-energized condi-
tions. This finding suggests that reserpine is able to inhibit
RND-4 efflux pump, as well as the other efflux systems in
J2315 and D1 strains. The addition of reserpine also
increased intracellular levofloxacin accumulation in D4
mutant [Fig. 2], suggesting that additional efflux systems
are expressed in the absence of this transporter, as previ-
ously reported [30].
Evaluation of acyl homoserine lactone accumulation in the 
growth medium of B. cenocepacia J2315 and the D1, D3 
and D4 mutants
To determine whether the inactivated RND efflux pumps
function in the transport of quorum sensing N-acyl
homoserine lactones (AHLs) we evaluated the export of
N-octanoyl homoserine lactone (C8-HSL). This quorum
sensing molecule was previously shown to be secreted by
B. cenocepacia [25]. Detection and quantification of C8-
HSL was measured using a heterologous plasmid-based
reporter assay. The plasmid pSCR1, which carries a -
galactosidase gene under the control of a C8-HSL respon-
sive B. cenocepacia promoter, was transformed into E. coli
DH5 and -galactosidase activity determined in the pres-
ence of culture supernatants derived from control and
mutant bacteria. The amount of this AHL in supernatants
derived from strain D1 did not differ from the parental
control. In contrast, the supernatant derived from strains
D3 and D4 accumulated 30% less C8-HSL in the medium
as compared to J2315 and D1 [Fig. 3]. These observations
suggest that the RND transporters encoded by BCAL1675
and BCAL2821 contribute to the transport of this AHL out
of B. cenocepacia.
Conclusion
Employing a recently developed mutagenesis strategy
[32], we successfully deleted three operons encoding RND
efflux pumps in B. cenocepacia strain J2315. This strain is
notoriously difficult to manipulate genetically, in part due
to its high level of antibiotic resistance, which precludes
the use of the most common selectable markers for gene
exchange. The mutagenesis strategy we employed has the
advantage of generating markerless deletions making it
possible to repeatedly use the same antibiotic resistance
cassette for subsequent gene deletions. We began our
study by deleting operons encoding RND-like efflux
pumps in B. cenocepacia J2315. The operons were selected
on the basis that they are the most closely related B. ceno-
cepacia efflux pumps to the Mex efflux pumps in P. aerugi-
nosa [15].
Our results demonstrate that only two of the three oper-
ons targeted for deletion contribute to the antibiotic
resistance of B. cenocepacia under the conditions tested
here, and that their function contributes to the resistance
of a small subset of antibiotics. Levofloxacin was one of
the antibiotics to which increased sensitivity could be
detected and our data indicate that RND-4 plays a role in
resistance to this drug. The inability to demonstrate
increased sensitivity to most classes of antibiotics sup-
ports the notion that there is functional redundancy in the
efflux pumps expressed by B. cenocepacia. Consequently,
multiple RND gene deletions in the same strain may be
required to understand better their role in intrinsic antibi-
otic resistance. The I-SceI mutagenesis system makes thisPage 5 of 11
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Intracellular accumulation of levofloxacin and effect of the addition of reserpineFigur  2
Intracellular accumulation of levofloxacin and effect of the addition of reserpine. Effect of the addition of reserpine 
on the intracellular accumulation of levofloxacin by B. cenocepacia J2315, D1, and D4 deleted mutants. Levofloxacin (40 g/ml) 
was added to the assay mixture to initiate the assay, and reserpine (8 g/ml) was added at the time point indicated by the 
arrow. Shown is the mean and standard deviation of values derived from three independent experiments.
BMC Microbiology 2009, 9:200 http://www.biomedcentral.com/1471-2180/9/200possible and these experiments are currently under way in
our laboratories.
Multidrug-resistance efflux pumps do not only confer
antibiotic resistance, but can also function to promote
colonization and persistence in the host [36]. For exam-
ple, Vibrio cholerae RND efflux systems are required for
antimicrobial resistance, optimal expression of virulence
genes, and colonization of the small intestine in an infant
mouse model of infection [37]. In this study, we found
reduced accumulation of AHLs quorum sensing signal
molecules in the growth medium of two of the RND dele-
tion mutants. These observations suggest that these
mutants have an AHL export defect that may alter quorum
sensing. Importantly, it has been demonstrated that B.
cenocepacia mutants lacking functional quorum sensing
systems are attenuated in a rat model of lung infection
[38]. It is likely that RND-3 and/or RND-4 might also be
required for survival in vivo and inhibition of their func-
tion may be beneficial not only to prevent quorum sens-
ing dependant phenomena such as biofilm formation but
also to increase antibiotic sensitivity during infection.
In summary, we have demonstrated that in B. cenocepacia,
RND efflux systems contribute to antibiotic resistance and
possibly to the secretion of quorum sensing molecules.
Furthermore our observations indicate that further inves-
tigation of RND efflux systems in B. cenocepacia is neces-
sary to better understand how this bacterium is able to
resist antibiotic treatments in the clinic and to chronically
infect cystic fibrosis patients.
Methods
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this study are listed
in Table 2. Bacteria were grown in Luria-Bertani (LB)
broth (Difco), with shaking at 200 rpm, or on LB agar, at
37°C. The antibiotic concentrations used were 100 g/ml
ampicillin, 50 g/ml gentamicin, 40 g/ml kanamycin, 50
g/ml trimethoprim, and 12.5 g/ml tetracycline for E.
coli, and 800 g/ml trimethoprim, and 300 g/ml tetracy-
cline for B. cenocepacia.
Molecular techniques
Manipulation of DNA was performed as described previ-
ously [39]. Restriction enzymes and T4 DNA ligase were
purchased from GE Healthcare and used following the
manufacturer's instructions. E. coli DH5 and E. coli
SY327 cells were transformed by the electroporation
method [39]. Plasmids were mobilized into B. cenocepacia
J2315 by triparental mating as described previously [40],
using E. coli DH5 carrying the helper plasmid pRK2013.
Gentamicin was used to counter select against the E. coli
donor and helper strains. All PCR reactions used the MJ
Mini Personal Thermal Cycler (BioRad). To amplify PCR
products Taq DNA polymerase, HotStar HiFidelity
Polymerase kit, Hot StarTaq DNA Polymerase or Qiagen
LongRange PCR kit (QIAGEN) were used and each reac-
tion supplemented with Q solution according to the man-
ufacturer's instructions. DNA fragments were cloned into
pGEM-T Easy vector (Promega) and sequenced using the
standard M13for and M13rev primers. Southern blot
analyses were performed as previously described [39].
MIC determinations
Determination of MIC (Minimal Inhibitory Concentra-
tion) for B. cenocepacia J2315 and the deletion mutants
D1, D3, and D4 was performed by streaking 1 × 104 cells
onto LB agar containing 2-fold dilutions of different
drugs. The following compounds were tested to determine
the resistance profile: aztreonam, ethidium bromide,
chloramphenicol, gentamicin, tobramicin, nalidixic acid,
ciprofloxacin, levofloxacin, norfloxacin, sparfloxacin,
ampicillin, ceftazidime, erythromycin, meropenem, pip-
eracillin, kanamycin, tetracycline, and trimethoprim.
Plates were incubated at 37°C for 3 days and the growth
was visually evaluated. The MIC was defined as the lowest
drug concentration that prevented visible growth. The
Evaluation of AHLs accumulation in the growth medium of B. cenocepacia J2315 and the D1, D3, and D4 mutant strainsFig re 3
Evaluation of AHLs accumulation in the growth 
medium of B. cenocepacia J2315 and the D1, D3, and 
D4 mutant strains. C8-HSL measurement using E. coli 
(pSCR1) as described in Methods. C8-HSL was extracted 
from spent supernatants, AHL levels were measured with a 
volume of extract corresponding to 109 CFU. Values of AHL 
accumulated in the supernatant are expressed in Miller Units 
and in percentage in relation to the wild-type strain. The 
experiments were performed in triplicate giving comparable 
results. Significantly differences in AHL levels with respect 
J2315 are indicated by an * (ANOVA: P < 0.05; F 13.02; Dun-
nett's multiple Comparison test).
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cas.
Mutagenesis
The mutagenesis procedure allows for the creation of
unmarked nonpolar gene deletions, as described by Flan-
nagan et al. [32]. Briefly, the upstream and downstream
DNA sequence that flanks (about 500 bp each) the
operon targeted for deletion were cloned into pGPISce-I.
This suicide plasmid contains a unique restriction site for
the endonuclease I-SceI. Mutagenesis plasmids were
mobilized by conjugation into B. cenocepacia J2315 where
they integrate into the chromosome by homologous
recombination. Exconjugants were selected in the pres-
ence of trimethoprim (800 g/ml) and the single crosso-
ver insertion of the mutagenic plasmid in the B.
cenocepacia genome was confirmed by PCR analysis. Sub-
sequently, a second plasmid, pDAISce-I (encoding the I-
SceI endonuclease) was introduced by conjugation. Site-
specific double-strand breaks take place in the chromo-
some at the I-SceI recognition site, resulting in tetracy-
cline-resistant (due to the presence of pDAI-SceI) and
trimethoprim-susceptible (indicating the loss of the inte-
grated mutagenic plasmid) exconjugants.
PCR amplifications of flanking regions for the construc-
tion of the mutagenesis plasmids were performed with the
HotStar HiFidelity Polymerase kit (Qiagen), and the spe-
cific amplifications conditions were optimized for each
primer pair, as indicated in Table 3. For the deletion of the
rnd-1 operon, we used KO1XL- KO1BL and KO1BR-
KO1KR primer pairs [Table 3]. The PCR fragments were
first cloned into the pGEM-T Easy vector (Promega) and
the resulting plasmids were digested with XbaI-BamHI and
BamHI-KpnI, respectively. The recovered fragments were
cloned together into pGPISce-I digested with XbaI and
KpnI, resulting in pOP1/pGPI-SceI plasmid. For the dele-
tion of the rnd-3 operon, PCR amplifications of flanking
regions were performed using the primer pair OP13LX-
OP13LB and OP13RB-OP13RE [Table 3] and the frag-
ments were again cloned into pGEM-T Easy. After diges-
tion with XbaI-BamHI and BamHI-EcoRI, respectively, the
fragments were cloned into pGPISce-I digested with XbaI
and EcoRI, resulting in pOP3/pGPI-SceI plasmid. For the
deletion of the rnd-4 operon, PCR amplifications of flank-
ing regions were performed using KO4XL-KO4NL and
KO4NR-KO4KR primers [Table 3]. After cloning into
pGEM-T Easy and digestion with XbaI-NdeI and NdeI-
KpnI, respectively, the fragments were cloned into
pGPISce-I digested with XbaI and KpnI, resulting in pOP4/
pGPI-SceI plasmid.
The mutagenesis plasmids were mobilized into B. cenoce-
pacia by conjugation and mutants were selected as
described above. Due to the high level of antibiotic resist-
ance displayed by B. cenocepacia J2315 we used 800 g/ml
trimethoprim and 300 g/ml tetracycline. As the trimeth-
oprim MIC in B. cenocepacia J2315 is very high (256 g/
Table 2: Strains and plasmids
Strain or plasmid Relevant characteristics Source and/or reference
B. cenocepacia strains
J2315 CF clinical isolate G. Manno
D1 J2315 BCAS0591-BCAS0593 This study
D3 J2315 BCAL1672-BCAL1676 This study
D4 J2315 BCAL2820-BCAL2822 This study
E. coli strains
DH5 F- 80dlacZM15 (lacZYA-argF)U169 endA1 recA1 hsdR17(rK- mK+) supE44 thi-1 gyrA96 relA1 Laboratory stock
SY327 araD (lac pro) argE(Am) recA56 nalA  pir; Rifr [43]
Plasmids
pGEM-T Easy Vector for PCR cloning, Ampr Promega
pGPISce-I oriR6K, Tpr, mob+, containing the ISce-I restriction site [32]
pRK2013 oricolE1, RK2 derivative, Kanr, mob+, tra+ [44]
pDAISce-I pDA12 encoding the ISce-I homing endonuclease [32]
pOP1/pGPI-SceI Plasmid for construction of D1 deletion mutant This study
pOP3/pGPI-SceI Plasmid for construction of D3 deletion mutant This study
pOP4/pGPI-SceI Plasmid for construction of D4 deletion mutant This study
pSCR1 Ampr, pQF50 containing PcepI-lacZ and cepR [42]
Ampr, ampicillin resistance; Kanr, kanamycin resistance; Rifr, rifampin resistance; Tetr, tetracycline resistance; Tpr, trimethoprim resistance.Page 8 of 11
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ml). The single crossover insertion of the mutagenic plas-
mid in the B. cenocepacia genome was confirmed by PCR.
Subsequently pDAI-SceI was introduced in the strain with
the single crossover by conjugation. Site-specific double-
strand breaks took place in the chromosome, resulting in
exconjugants resistant to tetracycline and susceptible to
trimethoprim. Also in this case we had to use a greater
amount of tetracycline (300 g/ml) respect to B. cenocepa-
cia K56-2 (100 g/ml), due to the high level of resistance
of J2315 strain. The desired gene deletions were first con-
firmed by PCR amplification using primers KO1F-KO1R,
CO13OPL-CO13OPR, and KO4F-KO4R for rnd-1, -3, and
-4, respectively, and then by Southern blot hybridization
of XhoI- (for D1 and D4 strains) or NotI- (for D3) cleaved
genomic DNA.
Levofloxacin accumulation assay
The accumulation of levofloxacin in B. cenocepacia J2315
was monitored by a fluorometric method, using the Perk-
inElmer LS3 fluorometer. All experiments were repeated
three times. B. cenocepacia J2315, D1 and D4 mutant were
cultured until the cells were in an exponential growth
phase (OD550 = 0.6). The cells were then harvested by cen-
trifugation at 4°C, washed once in 50 mM sodium phos-
phate buffer, pH 7.0, and resuspended in the same buffer
to a final OD550 equal to 20. The bacterial suspension was
preincubated for 10 min at 37°C in a shaking bath. Levo-
floxacin was added to a final concentration of 40 g/ml.
One-milliliter aliquots were collected at different time
points, chilled on ice, then centrifuged at 12000 × g for 3
min at 4°C. The pellets were washed once with 1 ml of
chilled 50 mM sodium phosphate buffer, pH 7.0 and
resuspended in 1 ml of 0.1 M glycine-HCl, pH 3.0. This
suspension was then lysed by incubation at room temper-
ature for 16 h, with vigorous shaking. After 16 h, the sam-
ples were then centrifuged at 12000 × g for 5 min at room
temperature and the fluorescence of the supernatant was
measured using the excitation and emission wavelengths
of 295 and 490 nm, respectively. Levofloxacin concentra-
tions were calculated using a standard curve of the antibi-
otic (concentration ranging from 0.42 g/ml to 6.38 g/
ml) in 0.1 M glycine-HCl buffer, pH 3.0. To correct for any
endogenous signal the fluorescence of a control cell lysate,
measured on samples not exposed to the drug, was sub-
tracted from the experimental values. The intracellular lev-
els of levofloxacin were expressed as drug accumulation in
109 cells, after counting of viable cells for each time point.
The accumulation of levofloxacin was determined at the
following time intervals: 0 min, 0 min+ drug, 2.5 min, 5
min, 10 min, 15 min, and 20 min. To determine whether
levofloxacin was actively effluxed from B. cenocepacia
Table 3: Primers used in this work



















a Restriction endonuclease sites incorporated in the oligonucleotide sequences are underlined.
b N/A indicates the absence of restriction site.
c The PCR cycling conditions used with these primers were: 95°C for 5 min followed by 30 cycles of 94°C for 15 s, 62°C or 52°C for 1 min 
respectively, and 72°C for 1 min, with a final extension at 72°C for 10 min.
d The PCR cycling conditions used with these primers were: 95°C for 15 min followed by 25 cycles of 94°C for 1 min, 52°C for 1 min, and 72°C for 
1 min, with a final extension at 72°C for 10 min.
e The PCR cycling conditions used with these primers were: 95°C for 5 min followed by 30 cycles of 94°C for 15 s, 54°C for 1 min, and 72°C for 1 
min, with a final extension at 72°C for 10 min.Page 9 of 11
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added 2.5 min after the addition of levofloxacin and the
samples were treated as described above.
Purification, detection and quantification of N-acyl 
homoserine lactone (AHLs)
The purification, detection and visualization of AHL sig-
nal molecules from culture supernatants were performed
as described previously [41]. Bacterial strains were inocu-
lated in 50 ml of half diluted LB and grown at 37°C with
constant agitation until OD600 reached 2.5. Organic
extractions with ethyl acetate (0.1% acetic acid) were per-
formed twice on each supernatant and extracts were dried
and resuspended in acidified ethyl acetate in 1/1000 of
the original volume. Quantification of AHLs was deter-
mined using the reporter plasmid pSCR1. This plasmid
contains the cepR gene and the cepI gene promoter con-
trolling the expression of a promoterless -galactosidase
(lacZ) gene and functions as a sensor of AHL molecules
[42]. Overnight cultures of E. coli DH5 carrying pSCR1
were normalized to an OD600 of 0.1 in a volume of 20 ml
LB containing 10 L of the AHL purified extract (prepared
as described above). 10 L of ethyl acetate were used as
negative control, while 100 nM of synthetic C8-HSL
(Sigma-Fluka) was used as positive control. Cultures were
then grown with agitation at 37°C for 6 h and -galactos-
idase activities were determined [42].
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